News
IBRX
5.37
-1.65%
-0.09
Biotech Stocks Facing FDA Decision In April 2024
NASDAQ · 9h ago
iBio, ImmunityBio, Mesoblast among healthcare movers
IBio, ImmunityBio, Mesoblast among healthcare movers. S&P 500 Health Care Sector +1.04% to 1717.5. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index. IBio, immunityBio, mesoblast are among the biggest gainers.
Seeking Alpha · 1d ago
Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 3d ago
ImmunityBio Price Target Raised to $5.00/Share From $4.00 by Piper Sandler
Dow Jones · 3d ago
ImmunityBio Is Maintained at Neutral by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $5
Benzinga · 3d ago
Weekly Report: what happened at IBRX last week (0318-0322)?
Weekly Report · 3d ago
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Sportradar Group AG shares jumped 10.7% to $11.17 on Wednesday. The company reported better-than-expected fourth-quarter results. Annovis Bio, Inc. Shares surged 25.6% after the company announced a 50-for-1 stock split. The Dow Jones index gained around 0.1% in Wednesday's session.
Benzinga · 03/20 15:41
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023
ImmunityBio reported earnings per share of -38 cents for the fourth quarter of 2023. The company reported revenue of $139,000. This was 595% better than the analyst estimate of $20,000 for the quarter. ImmunityBio is a biotechnology company.
Investorplace · 03/20 01:53
ImmunityBio: Q4 Earnings Insights
ImmunityBio reported its Q4 earnings results on March 19. The company missed estimated earnings by $0.38. ImmunityBio's revenue was up $66 thousand from the same period last year. Last quarter the company beat on EPS by  $0.08.
Benzinga · 03/19 21:25
Weekly Report: what happened at IBRX last week (0311-0315)?
Weekly Report · 03/18 09:06
Biotech's Role in Addressing the Pancreatic Cancer Emergency
Pancreatic cancer still has the highest mortality rate of all major cancers. American Cancer Society projecting a record year for new cancer cases in 2024. Researchers and the biotech sector are working diligently to improve the chances of those diagnosed with pancreatic cancer. Researchers at the Mayo Clinic made a discovery that advances knowledge of how the cancer spreads.
Barchart · 03/14 07:45
Weekly Report: what happened at IBRX last week (0304-0308)?
Weekly Report · 03/11 09:06
Showcasing Seeking Alpha's February 2024 New Analysts
Home Stock Ideas Quick Picks & Lists Showcasing Seeking Alpha's February 2024 New Analysts. Today we showcase a record 39 new analysts that joined in February 2024. Analysts cover a wide range of areas of interest, including value investing, dividend investing, growth stocks, and cryptocurrencies.
Seeking Alpha · 03/06 12:40
Immunitybio Announced Data From Phase 1 Pilot Study Showed N-803 Combined With Natural Killer Cells Could Reduce Viral Load In People Living With HIV
Benzinga · 03/05 14:12
Weekly Report: what happened at IBRX last week (0226-0301)?
Weekly Report · 03/04 09:06
ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
ImmunityBio's Anktiva's PDUFA date is April 23rd for the treatment of non-muscle-invasive bladder cancer. The company's stock is up 100% since my "Sell" recommendation in August. ImmunityBio secured a $300M deal with Infinity in January. The deal complicates the company's financial and regulatory risks.
Seeking Alpha · 02/27 10:09
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Freshpet shares gained 15.5% to $106.29 on Monday. The company reported better-than-expected fourth-quarter financial results. Akili, Inc. Shares jumped 126% after the company reported positive results from a clinical trial of an ADHD drug in Japan.
Benzinga · 02/26 18:57
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Intuitive Machines, Inc. Shares fell sharply in today's pre-market trading. The company's lunar lander, Odysseus, encountered a mishap during a touchdown near the moon's south pole. ZyVersa Therapeutics, Inc., and 23andMe Holding Co. Were among the stocks moving in pre- market trading.
Benzinga · 02/26 13:18
12 Health Care Stocks Moving In Monday's Pre-Market Session
ZyVersa Therapeutics (NASDAQ:ZVSA) stock increased by 44.8% to $1.16 during Monday's pre-market session. Agiliti (NYSE:AGTI) shares moved upwards by 27.09%. Altimmune and ImmunityBio shares also rose during the session. Losers ThermoGenesis Holdings and Cogent Biosciences.
Benzinga · 02/26 13:06
More
Webull provides a variety of real-time IBRX stock news. You can receive the latest news about Immunitybio Inc through multiple platforms. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its segment is focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Its platforms include antibody cytokine fusion proteins; DNA, RNA, and recombinant protein vaccine technologies, including self-amplifying RNA, second-generation adenovirus hAd5 vector and recombinant protein platforms; toll-like receptor activating adjuvants; natural killer (NK) cell therapy, including off-the-shelf NK cells, and autologous and allogenic memory-like cytokine-enhanced NK cells (M-ceNK); damage-associated molecular patterns inducers, including Aldoxorubicin and Nanatinostat. Its clinical pipeline consists of over 26 clinical trials of which 17 are in Phase I or III development, across 13 indications in liquid and solid tumors.